Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"NeurMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeurMedix Obtains FDA Authorization for Pivotal Phase 3 Alzheimer\u2019s Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"NeurMedix","sponsor":"BioVie","pharmaFlowCategory":"D","amount":"$3360.3 million","upfrontCash":"Undisclosed","newsHeadline":"BioVie Acquires Biopharma Assets from Privately Held NeurMedix","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"NeurMedix","sponsor":"BioVie","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by NeurMedix

    Menu

    NeurMedix

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              NeurMedix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix

              Details:

              The acquired assets include NE3107, a selective inhibitor of inflammatory ERK signaling that reduces neuroinflammation. It is an orally administered novel small molecule that inhibits inflammation-driven insulin resistance and major pathological inflammatory cascades.

              Lead Product(s): 17α-ethynyl-androst-5-ene-3,7,17-triol

              Therapeutic Area: Neurology Product Name: NE3107

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: BioVie

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition June 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NeurMedix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioVie Acquires Biopharma Assets from Privately Held NeurMedix

              Details:

              NeurMedix’s lead clinical drug candidate, NE3107, 17α-ethynyl-androst-5-ene-3,7,17-triol, is a first-in-class small molecule, orally administered, highly effective inhibitor of insulin resistance and the pathological inflammatory cascade and with a novel mechanism of action.

              Lead Product(s): 17α-ethynyl-androst-5-ene-3,7,17-triol

              Therapeutic Area: Neurology Product Name: NE3107

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: BioVie

              Deal Size: $3360.3 million Upfront Cash: Undisclosed

              Deal Type: Acquisition April 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NeurMedix

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NeurMedix Obtains FDA Authorization for Pivotal Phase 3 Alzheimer’s Trial

              Details:

              The trial will evaluate twice daily 20 mg oral NE3107 versus placebo for 30 weeks beginning with dose titration of 5 mg BID in weeks 1 and 2 and 10 mg BID in weeks 3-4, with 20 mg BID for weeks 5-30.

              Lead Product(s): 17α-ethynyl-androst-5-ene-3,7,17-triol

              Therapeutic Area: Neurology Product Name: NE3107

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 02, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY